Overview

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Status:
Recruiting

Trial end date:
2022-12-09

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborators:

George Clinical Pty Ltd
Parexel

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin